Behavioral and pharmacologic therapies for obesity

Nature Reviews Endocrinology

Volumn 6, Issue 10, 2010, Pages 578-588

  Vetter, Marion L ^a   Faulconbridge, Lucy F ^a   Webb, Victoria L ^a   Wadden, Thomas A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; AMFEBUTAMONE; AMFEPRAMONE; AMYLIN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; FENFLURAMINE; FLUOXETINE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; LEPTIN; LEPTIN RECEPTOR; LORCASERIN; MELANOCORTIN; MELANOCORTIN 3 RECEPTOR; METRELEPTIN; NALTREXONE; NEUROPEPTIDE Y1 RECEPTOR; PHENTERMINE; PLACEBO; PRAMLINTIDE; PROOPIOMELANOCORTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

ABDOMINAL PAIN; ANXIETY; APPETITE; ARCUATE NUCLEUS; BLOATING; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DIETARY INTAKE; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENERGY EXPENDITURE; ENERGY METABOLISM; FATIGUE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; GLUCOSE TOLERANCE; HEADACHE; HEART PALPITATION; HUMAN; HYPERSOMNIA; INJECTION SITE PAIN; INSOMNIA; JAUNDICE; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER INJURY; LONG TERM CARE; LOW CARBOHYDRATE DIET; LOW DRUG DOSE; LOW FAT DIET; MEDITERRANEAN DIET; MORBIDITY; MORNING DOSAGE; MORTALITY; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARESTHESIA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULSE RATE; RASH; RESISTANCE TRAINING; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SATIETY; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; TACHYCARDIA; THALAMUS MIDLINE NUCLEUS; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; EXERCISE; HUMANS; OBESITY; WEIGHT LOSS;

EID: 77956938588     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.121     Document Type: Review

References (126)

1. WHO. Obesity: Preventing and Managing the Global Epidemic (WHO, Geneva, 1998).
2. [No authors listed] Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. National Institutes of Health. Obes. Res. 6 (Suppl. 2), 51S-209S (1998).
3. National Heart, Lung, and Blood Institute (NHLBI) and the North American Association for the Study of Obesity (NAASO). The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (National Institutes of Health, Bethesda, MD, 2000).
4. Knowler, W. C. et al. reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. N. Engl. J. Med. 346, 393-403 (2002).
5. Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001).
6. Look AHEAD research Group et al. reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results from the Look AHEAD trial. Diabetes Care 30, 1374-1383 (2007).
7. Look AHEAD research Group et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity 14, 737-752 (2006).
8. Wing, r. r. reduction in weight and cardiovascular disease (CVD) risk factors in subjects with type 2 diabetes (T2DM): four-year results of Look AHEAD [abstract 06-0r]. Obesity 17 (Suppl. 2), S49 (2009).
9. Wadden, T. A. & Foster, G. D. Behavioral treatment of obesity. Med. Clin. North Am. 84, 441-461 (2000).
10. Wadden, T. A., Butryn, M. L. & Wilson, C. Lifestyle modification for the management of obesity. Gastroenterology 132, 2226-2238 (2007).
11. renjilian, D. A. et al. Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. J. Consult. Clin. Psychol. 69, 717-721 (2001).
12. Tate, D. F., Wing, r. r. & Winett, r. A. Using internet technology to deliver a behavioral weight loss program. JAMA 285, 1172-1177 (2001).
13. rothert, K. et al. Web-based weight management programs in an integrated health care setting: a randomized, controlled trial. Obesity 14, 266-272 (2006).
14. Tate, D. F., Jackvony, E. H. & Wing, r. r. A randomized trial comparing human e-mail counseling, computer-automated tailored counseling, and no counseling in an Internet weight loss program. Arch. Intern. Med. 166, 1620-1625 (2006).
15. Harvey-Berino, J. et al. Does using the Internet facilitate the maintenance of weight loss? Int. J. Obes. Relat. Disord. 26. 1254-1260 (2002).
16. Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans (US Department of Agriculture, US Department of Health and Human Services, Washington, DC, 2005).
17. Diabetes Prevention Program research Group. The Diabetes Prevention Program: description of lifestyle intervention. Diabetes Care 25, 2165-2171 (2002).
18. Brownell, K. D. The LEARN Program for Weight Management (American Health Publishing Dallas, TX, 2000).
19. Samaha, F. F. et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N. Engl. J. Med. 348, 2074-2081 (2003).
20. Nordmann, A. J. et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 166, 285-293 (2006).
21. Brand Miller, J., Hayne, S., Petocz, P. & Colagiuri, S. Low-glycemic index diets in the management of diabetes. Diabetes Care 26, 2261-2267 (2003).
22. Thomas, D. E., Elliott, E. J. & Baur, L. Low glycaemic index or low glycaemic load diets for overweight and obesity. Cochrane Database of Systematic Reviews, Issue 3. Art No.: CD005105 doi:10.1002/14651858.CD005105.pub2 (2007).
23. Shai, I. et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229-241 (2008).
24. Esposito, K. et al. Effects of a Mediterraneanstyle diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann. Intern. Med. 151, 306-314 (2009).
25. Buckland, G., Bach, A. & Serra-Majem, L. Obesity and the Mediterranean diet: a systematic review of observational and intervention studies. Obes. Rev. 9, 582-593 (2008).
26. Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P. & Schaefer, E. J. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss: a randomized trial. JAMA 293, 43-53 (2005).
27. Sacks, F. M. et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Engl. J. Med. 360, 859-873 (2009).
28. Fung, T. T. et al. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 119, 1093-1100 (2009).
29. Blair, S. N. & Leermakers, E. A. in Handbook of Obesity Treatment (eds Wadden, T. A. & Stunkard, A. J.) 283-300 (Guilford Press, New York, 2002).
30. Haskell, W. L. et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med. Sci. Sports Exerc. 39, 1423-1434 (2007).
31. Lee, C. D., Blair, S. N. & Jackson, A. S. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am. J. Clin. Nutr. 69, 373-380 (1999).
32. Stevens, J., Cai, J., Evenson, K. r. & Thomas, r. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am. J. Epidemiol. 156, 832-841 (2002).
33. Hu, F. B. et al. Adiposity as compared with physical activity in predicting mortality among women. N. Engl. J. Med. 351, 2694-2703 (2004).
34. Donnelly, J. E. et al. American College of Sports Medicine position stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med. Sci. Sports Exerc. 41, 459-471 (2009).
35. Bweir, S. et al. resistance exercise training lowers HbA1c more than aerobic training in adults with type 2 diabetes. Diabetol. Metab. Syndr. 10, 27 (2009).
36. Jakicic, J. M., Donnelly, J. E., Pronk, N. P., Jawad, A. F. & Jacobsen, D. J. Prescription of exercise intensity for the obese patient: the relationship between heart rate, VO2, and perceived exertion. Int. J. Obes. Relat. Metab. Disord. 19, 382-387 (1995).
37. Jakicic, J. M., Winters, C., Lang, W. & Wing, r. r. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. JAMA 282, 1554-1560 (1999).
38. Andersen, r. E. et al. Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial. JAMA 281, 335-340 (1999).
39. Dunn, A. L. et al. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA 281, 327-334 (1999).
40. Bravata, D. M. et al. Using pedometers to increase physical activity and improve health: a systematic review. JAMA 298, 2296-2304 (2007).
41. Brownell, K. D. & Horgen, K. B. Food Fight: The Inside Story of Americas Obesity Crisis and What We Can Do About It (Contemporary Books, Chicago, 2003).
42. rosenbaum, M. et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J. Clin. Invest. 115, 3579-3586 (2005).
43. Svetkey, L. P. et al. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA 299, 1139-1148 (2008).
44. Perri, M. G. et al. Effects of four maintenance programs on the long-term management of obesity. J. Consult. Clin. Psychol. 56, 529-534 (1988).
45. Wing, r. r., Tate, D. F., Gorin, A. A., raynor, H. A. & Fava, J. L. A self-regulation program for maintenance of weight loss. N. Engl. J. Med. 355, 1563-1571 (2006).
46. Jeffery, r. W., Wing, r. r., Sherwood, N. E. & Tate, D. F. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome? Am. J. Clin. Nutr. 78, 684-689 (2003).
47. Wing, r. r. & Hill, J. O. Successful weight loss maintenance. Annu. Rev. Nutr. 21, 323-341 (2001).
48. Wadden, T. A. et al. randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 353, 2111-2120 (2005).
49. James, W. P. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STOrM Study Group. Sibutramine Trial of Obesity reduction and Maintenance. Lancet 356, 2119-2125 (2000).
50. Sjöström, L. et al. randomized placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicenter Orlistat Study Group. Lancet 352, 167-172 (1998).
51. Davidson, M. H. et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281, 235-242 (1999).
52. Bray, G. A. & ryan, D. H. Drug treatment of the overweight patient. Gastroenterology 132, 2239-2252 (2007).
53. Lee, M. & Aronne, L. J. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am. J. Cardiol. 99 (Suppl.), 68B-79B (2007).
54. rucker, D., Padwal, r., Li, S. K., Curioni, C. & Lau, D. C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335, 1194-1199 (2007).
55. Filippatos, T. D. et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 31, 53-65 (2008).
56. U.S. Food and Drug Administration. Early communication about an ongoing safety review orlistat (marketed as Alli and Xenical) [online], http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatients andProviders/DrugSafetyInformationfor HeathcareProfessionals/ucm179166.htm (2009).
57. Torgerson, J. S., Hauptman, J., Boldrin, M. N. & Sjöström, L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes in the prevention of type 2 diabetes in obese patients. Diabetes Care 27, 155-161 (2004).
58. Digenio, A. G., Mancuso, J. P., Gerber, r. A. & Dvorak, r. V. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann. Intern. Med. 150, 255-262 (2009).
59. Wadden, T. A. et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch. Intern. Med. 161, 218-227 (2001).
60. Torp-Pedersen, C. et al. Cardiovascular response to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur. Heart J. 28, 2915-2923 (2007).
61. US Food and Drug Administration. Follow-up to the November 2009 early communication about an ongoing safety review of sibutramine, marketed as Meridia [online], http://www.fda. gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcare Professionals/ucm198206.htm (2010).
62. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorizations for sibutramine [online], http://www.ema.europa.eu/pdfs/ human/referral/sibutramine/3940810en.pdf (2010).
63. Haddock, C. K., Poston, W. S., Dill, P. L., Foreyt, J. P. & Ericsson, M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord. 26, 262-273 (2002).
64. Munro, J. F., MacCuish, A. C., Wilson, E. M. & Duncan, L. J. Comparison of continuous and intermittent anorectic therapy in obesity. Br. Med. J. 1, 352-354 (1968).
65. Bray, G. A. & Greenway, F. L. in Treatment of the Obese Patient (eds Kushner, r. F. & Bessesen, D. H.) 341-368 (Humana Press, New Jersey, 2007).
66. Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581-588 (1997).
67. Li, Z. et al. Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med. 142, 532-546 (2005).
68. Jones, D. Novel pharmacotherapies for obesity poised to enter the market. Nat. Rev. Drug Discov. 8, 833-834 (2009).
69. Flier, J. S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116, 337-350 (2004).
70. Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S. & Schwartz, M. W. Central nervous system control of food intake and body weight. Nature 443, 289-295 (2006).
71. Ahima, r. S. & Flier, J. S. Leptin. Annu. Rev. Physiol. 62, 413-437 (2000).
72. Greenway, F. L. et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J. Clin. Endocrinol. Metab. 94, 4898-4906 (2009).
73. Wadden, T. A. et al. Weight loss with naltrexone Sr/buprobion Sr combination therapy as an adjunct to behavior modification: the COr-BMOD trial. Obesity doi:10.1038/oby.2010.147.
74. Oommen, K. J. & Mathews, S. Zonisamide: a new antiepileptic drug. Clin. Neuropharmacol. 22, 192-200 (1999).
75. Gadde, K. M., Franciscy, D. M., Wagner, H. r. & Krishnan, K. r. Zonisamide for weight reduction in obese adults: a randomized controlled trial. JAMA 289, 1820-1825 (2003).
76. Landbloom, r. et al. Long term weight loss from a dose optimization study with zonisamide Sr and bupropion Sr [abstract 61-Or]. Obesity 16 (Suppl. 1), S63-S64 (2008).
77. Gadde, K. M. et al. A 24-week randomized controlled trial of VO-0521, a combination weight loss therapy, in obese adults [abstract 55-Or]. Obes. Res. 14, A17 (2006).
78. Aronne, L. J. et al. Weight loss with VI-0521 (phentermine/controlled release topiramate) stops progression toward type 2 diabetes in obese non-diabetic subjects. Diabetes 58, A32 (2009).
79. Gadde, K. M. & Allison, D. B. Combination therapy for obesity and metabolic disease. Curr. Opin. Endocrinol. Diabetes Obes. 16, 353-358 (2009).
80. Astrup, A. et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes. Res. 12, 1658-1669 (2004).
81. Roth, J. D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA 105, 7257-7262 (2008).
82. Trevaskis, J. L. et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 149, 5679-5687 (2008).
83. ravussin, E. et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17, 1736-1743 (2009).
84. Smith, S. r. et al. Effect of APD356, a selective 5-HT-2C agonist, on weight loss in a 4-week study of healthy obese patients [abstract]. Obes. Res. 13 (Suppl.), A1-A218 (2005).
85. Smith, S. r., Prosser, W., Donahue, D., Anderson, C. M. & Shanahan, W. APD356, an orally-selective 5-HT-2C agonist, reduces body weight in obese adult men and women [abstract]. Diabetes 55 (Suppl. 1), A80 (2006).
86. Thomsen, W. J. et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2c agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325, 577-587 (2008).
87. Smith, S. r., Weissman, N. J., Scott, S., Anderson, C. M. & Shanahan, W. r. Lorcaserin reduces body weight in obese and overweight subjects: behavioral modification and lorcaserin for overweight and obesity management, the BLOOM trial [abstract]. American Diabetes Association (ADA) 69th Annual Scientific Sessions, A96-LB (2009).
88. Maes, H. H., Neale, M. C. & Eaves, L. J. Genetic and environmental factors in relative body weight and human adiposity. Behav. Genet. 27, 325-341 (1997).
89. Wardle, J., Carnell, S., Haworth, C. M. & Plomin, r. Evidence for a strong genetic influence on childhood adiposity despite the force of the obesogenic environment. Am. J. Clin. Nutr. 87, 398-404 (2006).
90. Stunkard, A. J. et al. An adoption study of human obesity. N. Engl. J. Med. 314, 193-198 (1986).
91. Vogler, G. P., Sørensen, T. I., Stunkard, A. J., Srinivasan, M. r. & rao, D. C. Influences of genes and shared family environment on adult body mass assessed in an adoption study by a comprehensive path model. Int. J. Obes. Relat. Metab. Disord. 19, 40-45 (1995).
92. Hainer, V. et al. role of hereditary factors in weight loss and its maintenance. Physiol. Res. 57 (Suppl. 1), S1-S15 (2008).
93. Blakemore, A. I. & Froguel, P. Is obesity our genetic legacy? J. Clin. Endocrinol. Metab. 93 (Suppl. 1), S51-S56 (2008).
94. Dhillon, H. et al. Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice. relationship with body weight change. Regul. Pep. 92, 97-105 (2000).
95. Li, G., Mobbs, C. V. & Scarpace, P. J. Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes 52, 1951-1957 (2003).
96. Kalra, S. P. & Kalra, P. S. Gene-transfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life expectancy. Trends Pharmacol. Sci. 26, 488-495 (2005).
97. ranadive, S. A. & Vaisse, C. Lessons from extreme human obesity monogenic disorders. Endocrinol. Metab. Clin. North Am. 37, 733-751 (2008).
98. Stutzmann, F. et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their agedependent penetrance in multigenerational pedigrees. Diabetes 57, 2511-2518 (2008).
99. Farooqi, I. S. et al. Clinical spectrum of obesity and mutations in the melanocortin-4 receptor gene. N. Engl. J. Med. 348, 1085-1095 (2003).
100. Li, S. & Loos, r. J. Progress in the genetics of common obesity: size matters. Curr. Opin. Lipidol. 19, 113-121 (2008).
101. De Krom, M. et al. Common genetic variations in CKK, leptin, and leptin receptor genes are associated with specific human eating patterns. Diabetes 56, 276-280 (2007).
102. Frayling, T. M. et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889-894 (2007).
103. Cecil, J. E., Tavendale, r., Watt, P., Hetherington, M. M. & Palmer, C. N. An obesityassociated FTO gene variant and increased energy intake in children. N. Engl. J. Med. 359, 2558-2566 (2008).
104. Haupt, A. et al. Variation in the FTO gene influences food intake but not energy expenditure. Exp. Clin. Endocrinol. Diabetes 117, 194-197 (2009).
105. Speakman, J. r., rance, K. A. & Johnstone, A. M. Polymorphisms of the FTO gene are association with a variation in energy intake, but not energy expenditure. Obesity 16, 1961-1965 (2008).
106. Timpson, N. J. et al. The fat mass- and obesityassociated locus and dietary intake in children. Am. J. Clin. Nutr. 88, 971-978 (2008).
107. Gerken, T. et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 318, 1469-1472 (2007).
108. Tung, Y. C. L. et al. Hypothalamic-specific manipulation of Fto, the ortholog of the human obesity gene FTO, affects food intake in rats. PLoS ONE 5, e8771 (2010).
109. Loos, r. J. et al. Common variants near MC4r are associated with fat mass, weight, and risk of obesity. Nat. Genet. 40, 768-775 (2008).
110. Willer, C. J. et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat. Genet. 41, 25-34 (2009).
111. Thorleifsson, G. et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat. Genet. 41, 18-24 (2009).
112. Meyre, D. et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat. Genet. 41, 157-159 (2009).
113. Hofker, M. & Wijmenga, C. A supersized list of obesity genes. Nat. Genet. 41, 139-140 (2009).
114. Zolotukhin, S. Gene therapy for obesity. Expert Opin. Biol. Ther. 5, 347-357 (2005).
115. Ahima, r. S. Obesity gene therapy: slimming immature rats. Gene Therapy 10, 196-197 (2003).
116. Barsh, G. S. & Schwartz, M. W. Genetic approaches to studying energy balance: perception and integration. Nat. Rev. Genet. 3, 589-600 (2002).
117. Gardner, C. D. et al. Comparison of the Atkins, Zone, Ornish, and LEArN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 297, 969-977 (2007).
118. Stern, L. et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann. Intern. Med. 140, 778-785 (2004).
119. Foster, G. D. et al. A randomized trial of a lowcarbohydrate diet for obesity. N. Engl. J. Med. 348, 2082-2090 (2003).
120. Yancy, W. S. et al. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann. Intern. Med. 140, 769-777 (2004).
121. Brinkworth, G. D. et al. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia 47, 1677-1686 (2004).
122. Iqbal, N. et al. Effects of a low-intensity intervention that prescribed a low-carbohydrate vs. a low-fat diet in obese, diabetic participants. Obesity doi:10.1038/oby.2009.460.
123. Klemsdal, T. O. et al. Effects of a low glycemic load diet versus a low-fat diet in subjects with and without the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 20, 195-201 (2010).
124. Das, S. K. et al. Long-term effects of 2 energyrestricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALErIE: a 1-y randomized controlled trial. Am. J. Clin. Nutr. 85, 1023-1030 (2007).
125. Estruch, r. et al. Effects of a Mediterraneanstyle diet on cardiovascular risk factors: a randomized trial. Ann. Intern. Med. 145, 1-11 (2006).
126. Brehm, B. J. et al. One-year comparison of a high-monounsaturated fat diet with a highcarbohydrate diet in type 2 diabetes. Diabetes Care 32, 215-220 (2009).